

## AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

1. to 32. (Canceled)

33. (New) An isolated human or humanized antibody having the binding specificity of the IK17 antibody;

wherein the antibody comprises a variable light chain encoded by a nucleotide sequence of SEQ ID NO:1 and a variable heavy chain encoded by a nucleotide sequence of SEQ ID NO:2;

wherein the antibody is selected from the group consisting of: a monoclonal antibody (Mab), a fragment antibody (Fab), and a single chain fragment (scFv);

wherein the monoclonal antibody, fragment antibody or single chain fragment is specific for oxidation specific epitopes found on copper-induced oxidized low density lipoprotein (Cu-OxLDL) and malondialdehyde low density lipoprotein (MDA-LDL);

wherein the monoclonal antibody, fragment antibody or single chain fragment does not bind to native LDL;

wherein the monoclonal antibody, fragment antibody or single chain fragment inhibits uptake of Cu-OxLDL by macrophages; and

wherein the monoclonal antibody, fragment antibody or single chain fragment binds the epitopes *in vivo* at a detectably higher rate than the rate of binding to normal vasculature.

34. (New) The isolated human or humanized antibody according to claim 33, wherein the antibody is a monoclonal antibody.

35. (New) The isolated human or humanized antibody according to claim 33, wherein the antibody is a fragment antibody.

36. (New) The isolated human or humanized antibody according to claim 33, wherein the antibody is a single chain fragment.

37. (New) The isolated human or humanized antibody according to claim 33, wherein the antibody is human.

38. (New) The isolated human or humanized antibody according to claim 33, wherein the antibody is humanized.

39. (New) The isolated human or humanized antibody according to claim 33, wherein the antibody is detectably labeled.

40. (New) The isolated human or humanized antibody according to claim 33 further comprising a therapeutic agent covalently linked to the antibody.